| NCT ID | NCT07692763 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Aarhus |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-07-03 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-07-03 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Young adults aged 18-39 years with cancer often experience physical, psychological, and social challenges that affect their participation in everyday life and their health-related quality of life. Existing cancer rehabilitation services are rarely tailored to the specific needs of this age group. The Young Adults Taking Action (YATAC) programme was developed together with young adults with cancer, healthcare professionals, and researchers to provide age-specific rehabilitation that supports young adults in managing cancer-related challenges and returning to everyday life. The aim of this pilot randomized controlled trial is to evaluate the feasibility of conducting a larger trial of the YATAC programme in a municipal rehabilitation setting. The study will examine recruitment, retention, acceptability of randomization, data completeness, assessment burden, and adverse events. In addition, the study will provide preliminary estimates of the programme's effects on health-related quality of life and self-efficacy. Fifty young adults aged 18-39 years who are undergoing or have completed curative-intent treatment will be recruited through municipal cancer rehabilitation services in Aarhus Municipality, Denmark. Participants will be randomly assigned to receive either the 16-week YATAC programme or usual cancer rehabilitation services. The YATAC programme includes an individual needs assessment and goal setting, followed by group-based and individual sessions addressing physical activity, fatigue, sleep and cognitive challenges, mental health, sexuality and relationships, family and friends, nutrition, and education or work. Outcomes will be assessed at baseline and at 4, 6, and 12 months after enrolment.
Eligibility Criteria
Inclusion Criteria: * Between 18 and 39 years of age * Are currently undergoing or have completed curative-intent cancer treatment within the past five years * Can understand and communicate in Danish and provide informed consent independently * Have been referred to municipal cancer rehabilitation services in the Municipality of Aarhus Exclusion Criteria: * Diagnosed with cancer before the age of 18 * Previously or currently receive rehabilitation
Contact & Investigator
Marc Sampedro Pilegaard, PhD
PRINCIPAL INVESTIGATOR
Social Medicine and Rehabilitation, Gødstrup Hospital
Frequently Asked Questions
Who can join the NCT07692763 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07692763 currently recruiting?
Yes, NCT07692763 is actively recruiting participants. Contact the research team at maagesen@health.sdu.dk for enrollment information.
Where is the NCT07692763 trial being conducted?
This trial is being conducted at Aarhus, Denmark.
Who is sponsoring the NCT07692763 clinical trial?
NCT07692763 is sponsored by University of Aarhus. The principal investigator is Marc Sampedro Pilegaard, PhD at Social Medicine and Rehabilitation, Gødstrup Hospital. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.